23498-55-7

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
(3beta,5alpha,17E)-17-(hydroxyimino)androstan-3-yl acetate is used as a research compound for exploring its potential therapeutic properties. Its hormonal effects and complex molecular structure make it a valuable candidate for the development of new medications.
Used in Hormonal Therapy:
As a steroid with hormonal effects, (3beta,5alpha,17E)-17-(hydroxyimino)androstan-3-yl acetate can be used as a component in hormonal therapy for various medical conditions. Its potential applications may include treatment of hormonal imbalances or certain diseases that can be managed through hormonal regulation.
Used in Biological Research:
(3beta,5alpha,17E)-17-(hydroxyimino)androstan-3-yl acetate is also used in biological research to study the effects of androstane derivatives on biological systems. This can contribute to a better understanding of their mechanisms of action and potential applications in medicine.

Upstream product

• 1239-31-2 3β-acetoxy-5α-androstan-17-one 
• 17291-39-3 p-toluenesulfonate of 3β-acetoxy-5α-androstan-17β-ol 
• 1098-12-0 3β-acetoxy-5α-androstan-17-one 

Downstream Products

• 5424-40-8 3β,17β-diacetoxy-5α-androstane 
• 7148-51-8 5α-androst-16-en-3β-ol 
• 1239-31-2 3β-acetoxy-5α-androstan-17-one 

Relevant academic research and scientific papers

STEROIDS .LIII. TRANSFORMATION OF 3β-ACETOXY-5α-ANDROSTAN-17-ONE INTO 17α- AND 17β-AMINO DERIVATIVES OF 5α-ANDROSTAN-3β-OL

The epimeric 17α- and 17β-amino-5α-androstan-3β-ols were synthesized from 3β-acetoxy-5α-androstan-17-one.The configurations at the C17 atom were demonstrated by the 1H NMR method.

Steroidal N-Nitro-amines. Part 2. Denitroamination of Steroidal 12β-, 17β-, 20β-, and 23R-Nitro-amines

20β-Nitroaminopregn-5-en-3β-yl acetate (13a), 17β-nitroamino-5α-androstan-3β-yl acetate (14), and 12β-nitroamino-(25R)-5α-spirostan-3β-yl acetate (15a) have been prepared by nitrosation of the corresponding oximes, followed by reduction with sodium borohydride.The 23-nitro-imine (12), obtained by reaction of sarsasapogenin acetate (10) with nitrous acid and boron trifluoride-diethyl ether complex, was similarly reduced to give 23R-nitroamino-(20S,22S,25S)-5β-spirostan-3β-yl acetate (16).Denitroamination of (13a) was achieved by treatment with acetic anhydride and pyridine to give the acetates of pregna-5,20-dien-3β-ol (17), pregn-5-ene-3β,20β-diol (18), 17α-methyl-D-homo-androst-5-ene-3,17aβ-diol (19), and 17α-methyl-12a-methylene-C(12a)-homo-18-norandrost-5-en-3β-ol (20).Under the same conditions the nitro-amine (14) afforded the acetates of 5α-androst-16-en-3β-ol (27a), 17β-methyl-18-nor-5α-androst-12-en-3β-ol (28a), 17-methyl-18-nor-5α-androst-13(17)-en-3β-ol (29a), and 17β-methyl-18-nor-5α-androst-13-en-3β-ol (30a).Denitroamination of (15a) took place through the expected C-nor-D-homo rearrangement producing 14(13->12αH)abeo-(25R)-5α-spirost-13(18)-en-3β-yl acetate (31) in high yield and a minor amount of 14(13->12)abeo-(25R)-5α-spist-12-en-3β-yl acetate (32).The trans-stereochemistry of the β-hydrogen-elimination produced in the denitroamination of (16) was established by using labelled sarsasapogenin (10) biosynthesized by Agave attenuata from mevalonic acid.